Merrill delights in A$1.75bn CSL equity record breaker
Life sciences firm CSL broke the record for a non-documented Australian equity offer this week when it completed a A$1.75bn ($1.52bn) accelerated global share placement to help finance its agreed $3.1bn bid for American firm Talecris Biotherapeutics.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts